[1]
O. Karaman, “CD19 Chimeric Antigen Receptor (CAR) modified cytokine killer cells compared to classical CD19 CAR-T: advantages and disadvantages”, SEE J Immunol, vol. 8, no. CITIM, p. 062, Mar. 2025.